Science Explorer Back to mapMap
Discussion
Topic · Genetics

Chronic Lymphocytic Leukemia Research

Chronic Lymphocytic Leukemia Research is a research topic within Genetics. Science Explorer counts 54k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenström macroglobulinemia.

  • Chronic Lymphocytic Leukemia
  • Genomic Aberrations
  • BTK Inhibitors
  • Rituximab
  • Ibrutinib
  • Prognostic Factors
  • TP53 Mutation
  • Waldenström Macroglobulinemia
  • Immunoglobulin Mutation
  • Therapeutic Targets
Research works
54k
fractional, since 1950
In the world top 10%
5.5k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+14%
the tick is no change
Largest producer
United States
41% of the 10 largest, 2022-now
Chronic Lymphocytic Leukemia Research

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Chronic Lymphocytic Leukemia Research research?

By volume, the United States and China publish the most (3.1k and 1.2k works in 2022-now).

By volume, 2022-now

  1. 1 United States 3.1k works
  2. 2 China 1.2k works
  3. 3 Italy 563 works
  4. 4 France 406 works
  5. 5 Japan 395 works
  6. 6 India 394 works
  7. 7 United Kingdom 375 works
  8. 8 Germany 363 works
  9. 9 Brazil 345 works
  10. 10 Spain 329 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 41.4%China: 16.1%Italy: 7.6%France: 5.4%6 others listed: 29.5%41%largest
United States3,092 · 41.4%China1,199 · 16.1%Italy563 · 7.6%France406 · 5.4%6 others listed2,201 · 29.5%

Shares of the rows listed above, not of the whole node.

Which institutions lead Chronic Lymphocytic Leukemia Research research?

By volume in 2022-now, The University of Texas MD Anderson Cancer Center publishes the most Chronic Lymphocytic Leukemia Research research, followed by Harvard University and Mayo Clinic.

By volume, 2022-now

  1. 1 The University of Texas MD Anderson Cancer CenterUnited States 192 works
  2. 2 Harvard UniversityUnited States 181 works
  3. 3 Mayo ClinicUnited States 126 works
  4. 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 78 works
  5. 5 The Ohio State UniversityUnited States 62 works
  6. 6 Memorial Sloan Kettering Cancer CenterUnited States 58 works
  7. 7 Peking UniversityChina 54 works
  8. 8 Nanjing Medical UniversityChina 53 works
  9. 9 National Institutes of HealthUnited States 52 works
  10. 10 Cornell UniversityUnited States 47 works

Who are the leading researchers in Chronic Lymphocytic Leukemia Research?

The most-cited researchers publishing on Chronic Lymphocytic Leukemia Research include Ahmedin Jemal, Eric S. Lander and Mark J. Daly.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Eric S. Lander United States 524k citations
  3. 3 Mark J. Daly United States 403k citations
  4. 4 Stacey L. Gabriel United States 402k citations
  5. 5 Peer Bork Germany 396k citations
  6. 6 Robert John Tibshirani United States 396k citations
  7. 7 Guido Kroemer France 386k citations
  8. 8 Bert Vogelstein United States 373k citations
  9. 9 Gad A. Getz United States 364k citations
  10. 10 Elaine R. Mardis United States 346k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Chronic Lymphocytic Leukemia Research?

The most cited paper in Chronic Lymphocytic Leukemia Research is "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al., 2016), with 7,935 citations. Next come "Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia" (5,063) and "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" (4,010).

Most cited papers
#PaperReleasedCitations
1 The 2016 revision of the World Health Organization classification of lymphoid neoplasms Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al. · Blood Open access 15 Mar 2016 7,935
2 Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia George Adrian Calin, Calin Dan Dumitru, Masayoshi Shimizu et al. · Proceedings of the National Academy of Sciences Open access 14 Nov 2002 5,063
3 The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Rita Alaggio et al. · Leukemia Open access 22 Jun 2022 4,010
4 Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines Michael J. Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood Open access 23 Jan 2008 3,806
5 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells Brian J. Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine May 1996 3,681
All 99 most cited papers, with filters and sorting

Where is Chronic Lymphocytic Leukemia Research research done?

The largest centres of Chronic Lymphocytic Leukemia Research research in 2022-now are Houston (United States), Beijing (China), New York (United States) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Duarte, Lancaster and North Chicago.

Largest cities, 2022-now

  1. 1 HoustonUnited States 232 works
  2. 2 BeijingChina 212 works
  3. 3 New YorkUnited States 196 works
  4. 4 BostonUnited States 164 works
  5. 5 ParisFrance 143 works
  6. 6 LondonUnited Kingdom 116 works
  7. 7 São PauloBrazil 114 works
  8. 8 ShanghaiChina 101 works
  9. 9 TokyoJapan 100 works
  10. 10 RomeItaly 100 works

Where it is the local speciality

  1. DuarteUS · 23.0 works42×
  2. LancasterUS · 23.6 works30×
  3. North ChicagoUS · 25.9 works30×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Chronic Lymphocytic Leukemia Research than the world average.

See Chronic Lymphocytic Leukemia Research on the map

Where is the best place to study Chronic Lymphocytic Leukemia Research?

Among universities, judged by research, Harvard University, Kettering University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%60%mean 19.46%fractional works in this field (log) →share of work in the world top 10% →Kettering UniversityUniversity of MiamiHarvard UniversityChinese Academy of M…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 70.719.3%6.5×181 +8.8%
2Kettering UniversityUnited States 66.348.6%33.8×11 +646.2%
3Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 54.012.3%8.5×78 +84.8%
4University of MiamiUnited States 53.224.6%6.0×32 +69.1%
5Karolinska InstitutetSweden 49.516.2%5.8×28 -4.5%
6Columbia UniversityUnited States 49.216.1%3.1×30 +32.4%
7Vita-Salute San Raffaele UniversityItaly 48.513.2%15.6×17 +48.6%
8University of PennsylvaniaUnited States 48.214.9%3.9×36 +23.5%
9Monash UniversityAustralia 48.119.1%2.4×20 +99.7%
10Peking UniversityChina 46.510.3%3.0×54 +40.5%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Chronic Lymphocytic Leukemia Research, country by country

Is Chronic Lymphocytic Leukemia Research research growing?

Output in 2022-2025 was 14% higher than in 2018-2021, peaking in 2023. The fastest-growing topics are Chronic Lymphocytic Leukemia Research.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Chronic Lymphocytic Leukemia Research as a percentage of every work published that year, 0.045% in 2024.

still counting0.025%0.050%0.075%Chronic Lymphocytic Leukemia Research0.041% in 202519801990200020102020

Fractional works of Chronic Lymphocytic Leukemia Research over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Chronic Lymphocytic Leukemia Research10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Chronic Lymphocytic Leukemia Research. Posts are plain text and can be reported.